Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Profitability improved due to strong sales, particularly in the industrial and medical equipment markets, expanded sales to the industrial equipment market, an improved sales mix and the effect of higher sales. ¥47 million in costs related to measures addressing product defects was recorded as expenses for responding to quality issues involving certain products.
No applicable matters ("There are no applicable matters")
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥3,524 million (YoY +19.7%) |
| Operating profit | ¥80 million (YoY +427.5%) |
| Ordinary income | ¥112 million (YoY +238.7%) |
| Profit attributable to owners of the parent | ¥27 million (YoY +161.8%) |
| Net income per share | ¥3.82 |
| Equity ratio | End of the current fiscal period 78.7 / End of previous period 80.7 |
| Total assets | ¥19,366 million |
| Net assets | ¥15,234 million |
| Full-year earnings forecast | Net Sales ¥13,800 million (YoY +7.3%) / Operating profit ¥290 million (YoY +1.8%) / Ordinary income ¥320 million (YoY -16.8%) / Profit attributable to owners of the parent ¥130 million (YoY -38.2%) |
| Revision to Earnings Forecast | Not disclosed → 2Q cumulative Net Sales 7,000 / Operating profit 140 / Ordinary income 170 / Profit attributable to owners of the parent 60 / Full year Net Sales 13,800 / Operating profit 290 / Ordinary income 320 / Profit attributable to owners of the parent 130 |
| Annual Dividend Forecast | Previous-period results 80 → Current fiscal year forecast 80（0.0%） |
| Regional sales | Region Japan / Net Sales ¥2,058 million / Year on year against the same period last year ¥13.4 million, Region China / Net Sales ¥738 million / Year on year against the same period last year ¥54.1 million, Region Other Asia / Net Sales ¥412 million / Year on year against the same period last year ¥21.8 million, Region Europe / Net Sales ¥223 million / Year on year against the same period last year ¥-12.2 million, Region North and Central America / Net Sales ¥91 million / Year on year against the same period last year ¥59.6 million |
| Depreciation and amortization | ¥228,549 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 thousand, Costs related to measures addressing product defects ¥47,434 thousand |
| Disclosure regarding the going concern assumption | No applicable matters ("There are no applicable matters") |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 7,743,000 shares |
| Treasury Shares at Period-End | 467,662 shares |
| Factors Behind Changes in Business Performance | Profitability improved due to strong sales, particularly in the industrial and medical equipment markets, expanded sales to the industrial equipment market, an improved sales mix and the effect of higher sales. ¥47 million in costs related to measures addressing product defects was recorded as expenses for responding to quality issues involving certain products. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The industrial equipment market, including semiconductor manufacturing equipment and factory automation equipment, and the medical equipment market, including ultrasound endoscopes and ultrasound diagnostic systems, performed strongly. Profitability improved due to expanded sales to the industrial equipment market, an improved sales mix and the effect of higher sales. In addition, costs related to measures addressing product defects were recorded as expenses for responding to quality issues involving certain products.